Dr. Albert Carrión Puig

• 2016 - 2021: Doctorado (PhD) en “Identificación de biomarcadores pronósticos
  de agresividad en Cáncer de Próstata”, Universitat de Barcelona, Hospital
  Clínic, Barcelona, España. Calificación: Excelente Cum Laude.
• 2015: European Board of Urology Certification (EBU)
• 2015: Rotación externa en el Departamento de Urología, sección de Terapia
  Focal en Cáncer de Próstata bajo la supervisión del Prof. Mark Emberton,
  University College of London Hospital, Londres, Reino Unido.
• 2010 - 2015: Residencia en Urología (MIR), Universitat de Barcelona, Hospital
  Clínic, Barcelona, España.
• 2003 - 2009: Licenciatura en Medicina y Cirugía, Universitat Autónoma de
  Barcelona, Unidad Docente: Hospital Vall d’Hebrón, Barcelona, España.

• 2017 – actualidad: Colaborador Docente Universidad Autónoma de Barcelona
• 2022 -2023 : Profesor en la ESU-ESOU Virtual Masterclass on Muscle-invasive
  Bladder Cancer de la European Urology Association en 2022 y 2023.
  Ponente en el Congreso Nacional de Urología (Asociación Española de
  Urología) en 2021, 2022 y 2023 sobre Carcinoma Urotelial.
• Ponente en la MasterClass sobre Cáncer de Vejiga, Madrid 2023.
• Ponente en la Sesión Plenaria de la XXXI Reunión Nacional de los Grupos de
  Litiasis y Endourología, Laparoscopia y Robótica 2023 (tumor del tracto urinario
  superior).
• 2017: Profesor de Máster Uro-Oncología. Hospital Clínic de Barcelona. Universidad de Barcelona.
• 2013 - 2015: Colaborador docente de la Facultad de Medicina, Hospital Clínic de Barcelona (Universitat de Barcelona).

• 2021 – actualidad: Miembro del panel de expertos y redactor de las Guías
  Europeas de Urología en el panel de Cáncer de Vejiga Musculo-Invasivo y
  Metastásico.
• D419JC00001: Phase III global trial, randomized, open-label, multicenter study
  of Durvalumab and BCG administered with combination therapy compared to
  BCG monotherapy in patients with high-risk, BCG-naive non-muscle-invasive
  bladder cancer (POTOMAC). Sub-investigator.
• 202142756493BCL1003: Phase I study of edafinitinib intravesical delivery system in
  participants with non-muscle-invasive or muscle-invasive bladder cancer and
  select FGFR mutations or fusions. Sub-investigator. 2022.
• Endoluminal light-activated treatment of upper tract urothelial cancer (Enlighted)
  trial. Multicenter Phase 3 Pivotal Study to evaluate the safety and efficacy of
  TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the
  treatment of Low Grade Upper Tract Urothelial Cancer. Sub-investigator. 2023.
• Phase III Randomized, Open-label Multicenter Study to determine the efficacy
  and safety of Durvalumab in combination with tremelimumab and enfortumab
  vedotin or durvalumab in combination with enfortumab vedotin for perioperative
  treatment in patients ineligible for cisplatin undergoing radical cystectomy for
  muscle-invasive bladder cancer (VOLGA). Sub-investigator. 2022
• NCT05148728 (ClinicalTrials.gov identifier). Active Surveillance vs in-office
  fulguration for low-grade bladder cancer tumors. Sub-investigator. 2023

- J Alfred Witjes 1 , Harman Max Bruins , Albert Carrión 3 et al. European
Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder
Cancer: Summary of the 2023 Guidelines. Eur Urol. 2023 Oct 17:S0302-
2838(23)03073-7. doi: 10.1016/j.eururo.2023.08.016.

-Lozano F, Raventós CX, Carrion A, Dinarés C, Hernández J, Trilla E, Morote
J. Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive
Bladder Cancer Recurrences: Could Cystoscopy Be Substituted? Cancers
(Basel). 2023 Jul 19;15(14):3683. doi: 10.3390/cancers15143683.
- Fernando Lozano, Carles Raventós, Albert Carrión, Enrique Trilla.
Optimization biomarkers in the surveillance of non muscle invasive bladder
cancer Archivos Españoles Urología. 2022. 75(2):133-143.

- Albert Carrion; Ahmed Hussein; Eun Daniel; Abofazl Hosseini; Jose M
Gaya; Ronney Abaza; Xavier Bonet; Umar Iqbal; Randall Lee; Mathew Lee;
Ziho Lee; Carles Raventos; Oriol Moreno; Joan Palou; Alberto Breda;
Fernando Lozano; Francesc Vigues; Enrique Trilla; Khurshid Guru
Perioperative and functional Outcomes of Robot-assisted Ureteroenteric
Reimplantation: A Multicenter Study of Seven Referral Institutions. European
Urology Open Science. 2022; 35, pp. 47 - 53.
- Raventós Busquets CX, Semidey ME, Lozano Palacio F, Carrión Puig A,
Aula Olivar A, De Torres Ramírez IM, Trilla Herrera E.Is Tumor Budding a
New Predictor for Early Cystectomy in pT1 High- Grade Bladder Cancer?
Urol Int. 2021 Aug 5:1-9. doi: 10.1159/000517543. Online ahead of print.
- López-Molina C, Carrion A, Campistol M, Piñero A, Lozano F, Salvador C,
Raventós CX, Trilla E. Evaluating the impact of the learning curve on the
perioperative outcomes of robot-assisted radical cystectomy with
intracorporeal urinary diversion. Actas Urol Esp (Engl Ed). 2021 Nov
25:S2173- 5786(21)00134-7. doi: 10.1016/j.acuroe.2021.05.004.
- Carrion A, Raventos C, Lozano F, Gallardo I, Trilla E. A robot-assisted
complete urinary tract extirpation in a patient with simultaneous panurothelial
carcinoma: A case report. J Endourol Case Rep. 2020 Dec 29;6(4):483-486
- Lozano F, Raventos CX, Carrion A, Trilla E, Morote J. Current status of
genetic urinary biomarkers for surveillance of non-muscle invasive bladder
cancer: a systematic review. BMC Urol. 2020 Jul 14;20(1):99.- Carrion A, Ingelmo-Torres M, Lozano JJ, Montalbo R, D’Anna M, Mercader
C, Velez E, Ribal MJ, Alcaraz A, Mengual L. Prognostic classifier for
predicting biochemical recurrence in localized prostate cancer patients after
radical prostatectomy. Urol Oncol 2020 Nov 11;S1078-1439(20)30565-2.
- Fernandez Aparicio T, Galan Llopis JA, Cansino Alcaide R, Pérez Fentes D,
Cepeda Delgado M, Alvarez- Ossorio JL; en representación del grupo
español EPIUTUC; Grupo español EPIUTUC. Incidence of upper tract
urothelial carcinoma in Spain. Actas Urol Esp. 2020 Sep;44(7):512-518.
- Carrion A, Huguet J, Ribal MJ, Dominguez A, Bonet X, Servian P,
Mayordomo O, Ajami T, Piccola N, Freixa R, Diaz F, Lozano F, Raventos C, Morote J. Comparison of standard vs palliative management for bladder
cancer in patients older than 85 years: multicentre study of 317 de novo
tumours. Urol Oncol. 2020 Feb;38(2):40.e9-40.e15

- Carrion A, Ribal MJ, Morote J, Huguet J, Raventos C, Lozano F, Costa-Grau
M, Alcaraz A. A comparative study of different surgical techniques for the
management of distal ureter during laparoscopic radical nephroureterectomy.
Actas Urol Esp. 2019 Dec;43(10):543-550.

- Carrion A, Piñero A, Raventós C, Lozano F, Díaz F, Morote J.Comparison of
perioperative outcomes and complications of robot assisted radical
cystectomy with extracorporeal vs intracorporeal urinary diversion. Actas Urol
Esp. 2019 Jul-Aug;43(6):277-283.

- García-Cruz E, Ramón-Barceló C, Carrión-Puig A, Alcaraz A.
Multiparametric magnetic resonance imaging in prostate cancer detection..
Arch Esp Urol. 2019 May;72(4):374-380.
- Carrion A, Díaz F, Raventós C, Lozano F, Piñero A, Morote J.Comparison of
Outcomes between Standard and Palliative Management for High Grade
Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years. Urol
Int. 2019;102(3):277-283.
- Carrion A, D'Anna M, Costa-Grau M, Luque P, García-Cruz E, Franco A,
Alcaraz A. Office stent placement under local anesthesia is a safe and
efficient procedure for the management of multiple ureteral disorders. Actas
Urol Esp. 2018 Mar;42(2):126-132.
- García-Cruz E, Carrión A, Ajami T, Álvarez M, Correas MÁ, García B,
García JV, González C, Portillo JA, Romero-Otero J, Simón C, Torremadé J,
Vigués F, Alcaraz A. The Patient's Comorbidity Burden Correlates with the
Erectile Dysfunction Severity. Actas Urol Esp. 2018 Jan-Feb;42(1):57-63.
- Ingelmo-Torres M, Lozano JJ, Izquierdo L, Carrion A, Costa M, Gómez L,
Ribal MJ, Alcaraz A, Mengual L. Urinary microRNA-based prognostic
classifier for non-muscle invasive bladder cancer. Oncotarget. 2017 Mar
14;8(11):18238-18247.
- Carrion A, García-Cruz E, Fernandez C, D'Anna M, Melnick A, Peri L,
Franco A, Alcaraz A. Prior lubrication of the urethra does not reduce pain
perception in men undergoing flexible cystoscopy. Urol Int. 2016;97(4):392-
396.

- Mateu L, García-Cruz E, Asiaín I, Castañeda R, Carrión A, Huguet J, Ribal
MJ, Alcaraz A. A higher Charlson comorbidity index is related to more
aggressive characteristics in de novo vesical tumours. Actas Urol Esp. 2016
Jan-Feb;40(1):23-8.
- Carrion A, Huguet J, García-Cruz E, Izquierdo L, Mateu L, Musquera M,
Ribal MJ, Alcaraz A. Intraoperative prognostic factors and atypical patterns of
recurrence in patients with upper urinary tract urothelial carcinoma treated
with laparoscopic radical nephroureterectomy. Scand J Urol. 2016
Aug;50(4):305-12.

- Peri Ll, Musquera M, Vilaseca A, Carrión A, Castañeda R, García-Cruz E,
Ribal MJ, Alcaraz A. Perioperative outcome and female sexual function after
laparoscopic transvaginal NOTES-assisted nephrectomy. World J Urol. 2015
Apr 23.
- Mateu L, Huguet J, Carrión A, García-Cruz E, Izquierdo L, Musquera M,
Ribal MJ, Alcaraz A. Predictors, pathological characteristics and outcomes of
bladder recurrences following nephroureterectomy. Actas Urol Esp. 2015 Apr
13. doi: 10.1016/j.acuro.2015.02.006.
- Carrión Puig A., Huguet J., Ribal MJ, Alcaraz A. Metastasis de origen
Urotelial. Tiene sentido pensar en la metastasectomía? (Urothelial
metastases. The role of metastasectomy). Annals 2014; 40.
- García-Cruz E, Gosálbez D, Sallent A, Piqueras M, Leibar-Tamayo A,
Romero-Otero J, Castañeda-Argaiz R, Carrión A, Asiain I, Mateu L, Luque
P, Alcaraz A. Erectile Dysfunction but Not Hormonal Levels Are Related to
Higher Estimated Mortality Risk Using Charlson Comorbidity Index. J Men's
Health. September 2014, 11(3): 109-114.
- García-Cruz E, Leibar-Tamayo A, Romero-Otero J, Asiaín I, Carrión A,
Castañeda R, Mateu L, Luque P, Cardeñosa O, Alcaraz A. Marked
Testosterone Deficiency-Related Symptoms May be Associated to Higher
Metabolic Risk in Men with Low Testosterone Levels. J Sex Med. 2014 Jun
26.

- García-Cruz E, Piqueras M, Huguet J, Ribal MJ, Vilaseca A, Gosálbez D,
Castañeda-Argáiz R, Carrión A, Alcover J, Alcaraz A. Higher second fourth
digit ratio predicts higher incidence of prostate cancer in prostate biopsy.
Arch Esp Urol. 2012.

- García-Cruz E, Carrión Puig A, García-Larrosa A, Sallent A, Castañeda-
Argáiz R, Piqueras M, Ribal MJ, Leibar-Tamayo A, Romero-Otero J, Alcaraz
A. Higher sex hormone-binding globulin and lower bioavailable testosterone
are related to prostate cancer detection on prostate biopsy. Scand J Urol.
2012.

- García-Cruz E, Castañeda-Argáiz R, Carrión A, Alcover J, Sallent A, Leibar-
Tamayo A, Romero-Otero J, Alcaraz A. Preoperative Hormonal Pattern in
Patients Undergoing Radical Prostatectomy due to Prostate Cancer. Actas
Urol Esp. 2012 Dec 12.

• Español
• Inglés
• Catalán